NCT05096182Active, not recruiting
Long-Term Follow-up of Patients With Chronic Kidney Disease Treated With Cellgram-CKD
Long-term Follow-up of Patients With Chronic Kidney Disease Who Had Administered Cellgram-CKD in PMC-P12 Study
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov. Identifier: NCT05042206).
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 10 (actual)
- First submitted
- 15 Oct 2021
- Start date
- 10 Mar 2022
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Pharmicell Co., Ltd.
- Diseases
- Chronic kidney disease
- NCT number
- NCT05096182
What you commit to
- Study type: Observational
- Participants enrolled: 10
- From 10 Mar 2022 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not Applicable
Who the study is looking for
- Those who participated in the PMC-P-12 clinical trial and received Cellgram-CKD
- Subjects who consented in writing to this long-term follow-up study
Age in the registry: 19 years to 79 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.